Product Images Levetiracetam

Each tablet of Levetiracetam USP contains 1,000 mg of the medicine. It is a prescription-only drug and should be stored between 15°C-30°C. Pharmacist advice to give the medication guide along with medicine to each patient. The drug is manufactured by MSN Laboratories Private Limited and supplied in a tight, light-resistant container with a child-resistant closure. Usual dosage instructions can be found in the package insert. Novadoz Pharmaceuticals LLC distributes it in Piscataway, NJ.*

Levetiracetam Tablets, USP are available in a bottle of 120 tablets, each containing 500 mg of Levetiracetam, USP. The usual dosage can be found in the package insert. The tablets should be stored between 20° to 25°C (68° o 77°F). A pharmacist should dispense this medication in a tight, light-resistant container with a chic-resistant closure. This medication is manufactured by MSN Laboratories Private Limited in India and distributed by Novadoz Pharmaceuticals LLC in New Jersey. A medication guide is included and should be given to each patient.*

Levetiracetam is a prescription medication available in the form of film-coated tablets. Each tablet contains 750mg of Levetiracetam, USP. It is recommended that the accompanying Medication Guide be dispensed to each patient. The package insert contains complete dosage recommendations. Novadoz Pharmaceuticals LLC is the distributor, and MSN Laboratories Private Limited is the manufacturer of this medication. It should be stored at a temperature between 20°C to 25°C (68°F to 77°F). If you need to store it, it is essential to keep it in an air-tight, light-resistant container.*

This is a description of the results of a study comparing a placebo group (N=104) to a group taking a dose of 3000 mg/day of the drug Levetiracetam (N=180). The percentages displayed represent the rates of some outcome, but the text does not provide enough information to determine what that outcome is.*

The text shows the percentage of patients in a study who received either a placebo or levetiracetam. The placebo group consisted of 97 patients and represented 44.6% of the total while the levetiracetam group consisted of 101 patients and represented 19.6% of the total. It is not clear what the study was about.*

This text indicates the percentage of participants in a study who were in the placebo group and the group taking levetiracetam. The study involved 51 individuals who were assigned to the placebo group and 58 who were assigned to the levetiracetam group. Further information is not available.*